Idorsia Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

IdorsiaDer Gewinn des Unternehmens wird voraussichtlich um 8.9% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 28.4% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 15.4% pro Jahr wachsen.

Wichtige Informationen

-8.1%

Wachstumsrate der Gewinne

-4.9%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	33.8%
Wachstumsrate der Einnahmen	35.6%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	18 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Idorsia Ltd (VTX:IDIA) Stock Rockets 26% But Many Are Still Ignoring The Company

May 30

Idorsia Ltd (VTX:IDIA) Analysts Are Reducing Their Forecasts For This Year

May 26

Idorsia Ltd (VTX:IDIA) Analysts Just Slashed Next Year's Revenue Estimates By 17%

May 01

Industry Analysts Just Made A Captivating Upgrade To Their Idorsia Ltd (VTX:IDIA) Revenue Forecasts

Apr 05

Need To Know: Analysts Are Much More Bullish On Idorsia Ltd (VTX:IDIA) Revenues

Mar 10

Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry

Mar 08

There's No Escaping Idorsia Ltd's (VTX:IDIA) Muted Revenues Despite A 37% Share Price Rise

Dec 28

Gewinn- und Umsatzwachstumsprognosen

SWX:IDIA - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CHF Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	411	-158	N/A	-219	3
12/31/2025	220	-362	-385	-361	5
12/31/2024	99	-384	-496	-482	4
3/31/2024	141	-56	-504	-498	N/A
12/31/2023	152	-298	-639	-629	N/A
9/30/2023	185	-374	-751	-739	N/A
6/30/2023	126	-814	-874	-859	N/A
3/31/2023	113	-843	-889	-871	N/A
12/31/2022	97	-828	-886	-859	N/A
9/30/2022	48	-887	-868	-836	N/A
6/30/2022	44	-810	-788	-756	N/A
3/31/2022	34	-728	-719	-678	N/A
12/31/2021	35	-635	-621	-590	N/A
9/30/2021	36	-520	-542	-515	N/A
6/30/2021	27	-499	-513	-491	N/A
3/31/2021	74	-429	-419	-409	N/A
12/31/2020	72	-445	-374	-365	N/A
9/30/2020	70	-450	-379	-367	N/A
6/30/2020	69	-451	-417	-400	N/A
3/31/2020	22	-507	-478	-459	N/A
12/31/2019	24	-494	-481	-462	N/A
9/30/2019	61	-460	-479	-461	N/A
6/30/2019	61	-459	-445	-430	N/A
3/31/2019	61	-414	-404	-391	N/A
12/31/2018	61	-386	-367	-353	N/A
9/30/2018	209	-213	-81	-63	N/A
6/30/2018	203	-165	-39	-25	N/A
12/31/2017	190	-17	N/A	115	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IDIA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IDIA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IDIA wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IDIADie Einnahmen des Unternehmens (28.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Swiss (4.4% pro Jahr).

Hohe Wachstumseinnahmen: IDIADie Einnahmen des Unternehmens (28.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IDIA in 3 Jahren voraussichtlich hoch sein wird

Idorsia Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates fall by 16%

Consensus revenue estimates fall by 44%

Price target decreased by 17% to CHF1.72

Consensus estimates of losses per share improve by 14%

Price target decreased by 11% to CHF4.79

Idorsia Ltd Updates Earnings Guidance for the Year 2023

Recent updates

Idorsia Ltd Receives Approval from the European Commission for JERAYGO™

Idorsia Ltd Approves Board Appointments

Consensus revenue estimates fall by 16%

Idorsia Ltd (VTX:IDIA) Stock Rockets 26% But Many Are Still Ignoring The Company

Consensus revenue estimates fall by 44%

Idorsia Ltd (VTX:IDIA) Analysts Are Reducing Their Forecasts For This Year

Full year 2023 earnings released: CHF1.67 loss per share (vs CHF4.67 loss in FY 2022)

Idorsia Ltd to Report Nine Months, 2024 Results on Oct 29, 2024

Idorsia Ltd (VTX:IDIA) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Industry Analysts Just Made A Captivating Upgrade To Their Idorsia Ltd (VTX:IDIA) Revenue Forecasts

Price target decreased by 17% to CHF1.72

Need To Know: Analysts Are Much More Bullish On Idorsia Ltd (VTX:IDIA) Revenues

Idorsia Ltd (VTX:IDIA) Stock Catapults 38% Though Its Price And Business Still Lag The Industry

There's No Escaping Idorsia Ltd's (VTX:IDIA) Muted Revenues Despite A 37% Share Price Rise

Consensus estimates of losses per share improve by 14%

Idorsia Ltd Announces New Phase 3 Data with Aprocitentan for Patients with Resistant Hypertension Presents At the American Society of Nephrology Kidney Week 2023

Price target decreased by 11% to CHF4.79

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue and earnings growth

Idorsia Ltd Updates Earnings Guidance for the Year 2023

Price target decreased by 9.9% to CHF5.91

Price target decreased by 8.6% to CHF9.36

The Idorsia Ltd (VTX:IDIA) Analysts Have Been Trimming Their Sales Forecasts

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus estimates of losses per share improve by 11%

Idorsia Ltd to Report Q1, 2024 Results on Apr 25, 2024

Sosei Group Corporation (TSE:4565) entered into an agreement to acquire Idorsia Pharmaceuticals Japan Ltd/Idorsia Pharmaceuticals Korea Co., Ltd from Idorsia Ltd (SWX:IDIA) for JPY 65 billion.

Price target decreased by 12% to CHF10.24

New major risk - Share price stability

Idorsia Ltd's (VTX:IDIA) P/S Still Appears To Be Reasonable

Idorsia Launches Quviviq (Daridorexant) in Switzerland – A First-In-Class Treatment for Chronic Insomnia Disorder to Improve Both Nighttime Symptoms and Daytime Functioning

Price target decreased by 14% to CHF11.60

Price target decreased by 9.9% to CHF13.72

Price target decreased by 12% to CHF13.46

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 12% to CHF13.46

Consensus EPS estimates fall by 14%

Price target decreased by 7.8% to CHF15.45

Price target decreased by 7.6% to CHF16.29

Idorsia Ltd Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Idorsia Ltd Provides Earnings Guidance for the Year 2023

No longer forecast to breakeven

Idorsia Ltd to Report Q3, 2023 Results on Oct 24, 2023

Forecast to breakeven in 2025

Idorsia Ltd Submits New Drug Application to the US FDA for Aprocitentan for Treatment of Patients with Difficult-to-Control Hypertension

Price target decreased to CHF18.17

Idorsia Ltd Announces Long-Term Safety and Tolerability Results with Daridorexant in Patients with Insomnia Disorder Published in CNS Drugs

Idorsia Ltd Announces Swissmedic Approves QUVIVIQ (daridorexant) – A First-In-Class Treatment for Chronic Insomnia Disorder to Improve Both Nighttime Symptoms and Daytime Functioning

No independent directors

The Janssen Pharmaceutical Companies, in Collaboration with Idorsia Ltd, Announce Results from the Phase 3 Precision Study

The Janssen Pharmaceutical Companies, in Collaboration with Idorsia Ltd, Announce Results from the Phase 3 Precision Study

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Consensus forecasts updated

Idorsia Ltd Provides Earnings Guidance for the Year 2022

Price target decreased to CHF23.41

Now 21% undervalued after recent price drop

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Idorsia Ltd to Report Q1, 2023 Results on Apr 25, 2023

Now 22% undervalued after recent price drop

Idorsia Ltd Announces Positive Phase 3 Study with Aprocitentan Demonstrates Significant Antihypertensive Efficacy in Patients with Resistant Hypertension

Idorsia Ltd Announces Phase 2A Study Results in Binge Eating Disorder

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

No independent directors

Idorsia Ltd to Report Fiscal Year 2022 Results on Feb 07, 2023

Idorsia Ltd and Idorsia Pharmaceuticals Japan Announces Availability of Pivlaz™ (Clazosentan) to Physicians in Japan to Start Treating Asah Patients

We Think Idorsia (VTX:IDIA) Has A Fair Chunk Of Debt

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind